Just another point here.
Oncologists are voting on their feet, they had no other options and now have significant response rates. And even though SD doesn’t form part of Objective Response Rates (ORR) having no added toxicity and stopping the growth of cancer is significant. Some patients with 6 lines of therapy in the US and Aus means the peak of options. To get 80% response is significant.
I’d also put a question to shareholders.
Would you prefer BP make an offer now without knowing the full scope of CF33 OR wait until IMU prove the therapy in spades to get a much larger buyout/license fee? One year could add literally billions to the market value.
Iv said it before, but Keytruda was deemed a largely unimportant therapy that Merck acquired by default in their M&A process, it wasn't until another BP saw benefit did they take notice… IMU will keep producing the data, the more they produce from here the better the outcome.
Patience is key.
